Giovanna Panzeca

Dr. Giovanna Panzeca

DBCF, University of Siena, Siena, Tuscany, Italy
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

7 November 2026 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
AFAnna Fontana
Anna Fontana
Gabriele CarulloGabriele Carullo
Gabriele Carullo
Giovanna PanzecaGiovanna Panzeca
Giovanna Panzeca
Sabrina MorelliSabrina Morelli
Sabrina Morelli
APAntonella Piscioneri
Antonella Piscioneri
GCGiuseppe Campiani
Giuseppe Campiani

4 January 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Gabriele CarulloGabriele Carullo
Gabriele Carullo
FFFederica Falbo
Federica Falbo
VTValeria Tudino
Valeria Tudino
JSJiazhao Song
Jiazhao Song
MFMarianna Fava
Marianna Fava
GCGiuseppe Campiani
Giuseppe Campiani

4 July 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Gabriele CarulloGabriele Carullo
Gabriele Carullo
NONoemi Orsini
Noemi Orsini
IPIlaria Piano
Ilaria Piano
LPLuca Pozzetti
Luca Pozzetti
APAlessandro Papa
Alessandro Papa
GCGiuseppe Campiani
Giuseppe Campiani

2 July 2024 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
Gabriele CarulloGabriele Carullo
Gabriele Carullo
SRSara Rossi
Sara Rossi
VGValentina Giudice
Valentina Giudice
APAlex Pezzotta
Alex Pezzotta
UCUgo Chianese
Ugo Chianese
GCGiuseppe Campiani
Giuseppe Campiani

19 July 2023 in Marine Drugs
Verified
Journal Article
Open access
PDF file
Daniela CarboneDaniela Carbone
Daniela Carbone
CPCamilla Pecoraro
Camilla Pecoraro
Giovanna PanzecaGiovanna Panzeca
Giovanna Panzeca
GXGeng Xu
Geng Xu
MRMargot Roeten
Margot Roeten
BPBarbara Parrino
Barbara Parrino
A new series of nortopsentin analogs, in which the central imidazole ring of the natural lead was replaced by a 1,3,4-oxadiazole or 1,3,4-thiadiazole moiety, was efficiently synthesized. The antiproliferative activity of all synthesized derivatives was evaluated against five pancreatic ductal adenocarcinoma (PDAC) cell lines, a primary culture and a gemcitabine-resistant variant. The five more potent compounds elicited EC50 values in the submicromolar–micromolar range, associated with a significant reduction in cell migration. Moreover, flow cytometric analysis after propidium iodide staining revealed an increase in the G2-M and a decrease in G1-phase, indicating cell cycle arrest, while a specific ELISA demonstrated the inhibition of CDK1 activity, a crucial regulator of cell cycle progression and cancer cell proliferation.